151 related articles for article (PubMed ID: 38227097)
41. Clinicopathological significance of CBX3 in colorectal cancer: An intensive expression study based on formalin-fixed and paraffin-embedded tissues.
Wang H; Zhao W; Wang J; Zhang Z
Pathol Int; 2022 Feb; 72(2):107-116. PubMed ID: 35048461
[TBL] [Abstract][Full Text] [Related]
42. Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients.
Kunzmann AT; Proença MA; Jordao HW; Jiraskova K; Schneiderova M; Levy M; Liska V; Buchler T; Vodickova L; Vymetalkova V; Silva AE; Vodicka P; Hughes DJ
Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1891-1899. PubMed ID: 31367996
[TBL] [Abstract][Full Text] [Related]
43.
Kim HS; Kim CG; Kim WK; Kim KA; Yoo J; Min BS; Paik S; Shin SJ; Lee H; Lee K; Kim H; Shin EC; Kim TM; Ahn JB
Front Cell Infect Microbiol; 2023; 13():1101291. PubMed ID: 36960042
[TBL] [Abstract][Full Text] [Related]
44.
Yang Z; Ji G
Oncol Lett; 2019 Aug; 18(2):975-982. PubMed ID: 31423156
[TBL] [Abstract][Full Text] [Related]
45. Analysis of
Guven DC; Dizdar O; Alp A; Akdoğan Kittana FN; Karakoc D; Hamaloglu E; Lacin S; Karakas Y; Kilickap S; Hayran M; Yalcin S
Biomark Med; 2019 Jun; 13(9):725-735. PubMed ID: 31157977
[No Abstract] [Full Text] [Related]
46. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21.
Yang Y; Weng W; Peng J; Hong L; Yang L; Toiyama Y; Gao R; Liu M; Yin M; Pan C; Li H; Guo B; Zhu Q; Wei Q; Moyer MP; Wang P; Cai S; Goel A; Qin H; Ma Y
Gastroenterology; 2017 Mar; 152(4):851-866.e24. PubMed ID: 27876571
[TBL] [Abstract][Full Text] [Related]
47. Replication Study:
Repass J;
Elife; 2018 Mar; 7():. PubMed ID: 29533182
[TBL] [Abstract][Full Text] [Related]
48. A newly developed PCR-based method revealed distinct Fusobacterium nucleatum subspecies infection patterns in colorectal cancer.
Bi D; Zhu Y; Gao Y; Li H; Zhu X; Wei R; Xie R; Wei Q; Qin H
Microb Biotechnol; 2021 Sep; 14(5):2176-2186. PubMed ID: 34309194
[TBL] [Abstract][Full Text] [Related]
49. Clinicopathological differences of high
Wang Y; Wen Y; Wang J; Lai X; Xu Y; Zhang X; Zhu X; Ruan C; Huang Y
Front Microbiol; 2022; 13():945463. PubMed ID: 36406461
[TBL] [Abstract][Full Text] [Related]
50.
Ye X; Wang R; Bhattacharya R; Boulbes DR; Fan F; Xia L; Adoni H; Ajami NJ; Wong MC; Smith DP; Petrosino JF; Venable S; Qiao W; Baladandayuthapani V; Maru D; Ellis LM
Cancer Prev Res (Phila); 2017 Jul; 10(7):398-409. PubMed ID: 28483840
[TBL] [Abstract][Full Text] [Related]
51. Fusobacterium nucleatum-derived small extracellular vesicles facilitate tumor growth and metastasis via TLR4 in breast cancer.
Li G; Sun Y; Huang Y; Lian J; Wu S; Luo D; Gong H
BMC Cancer; 2023 May; 23(1):473. PubMed ID: 37221488
[TBL] [Abstract][Full Text] [Related]
52. A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer.
Yuan D; Tao Y; Wang H; Wang J; Cao Y; Cao W; Pan S; Yu Z
Invest New Drugs; 2022 Oct; 40(5):884-894. PubMed ID: 35727391
[TBL] [Abstract][Full Text] [Related]
53. The presence of bacteria varies between colorectal adenocarcinomas, precursor lesions and non-malignant tissue.
Bundgaard-Nielsen C; Baandrup UT; Nielsen LP; Sørensen S
BMC Cancer; 2019 Apr; 19(1):399. PubMed ID: 31035942
[TBL] [Abstract][Full Text] [Related]
54. Long non-coding RNA EVADR induced by Fusobacterium nucleatum infection promotes colorectal cancer metastasis.
Lu X; Xu Q; Tong Y; Zhang Z; Dun G; Feng Y; Tang J; Han D; Mao Y; Deng L; He X; Li Q; Xiang Y; Wang F; Zeng D; Tang B; Mao X
Cell Rep; 2022 Jul; 40(3):111127. PubMed ID: 35858553
[TBL] [Abstract][Full Text] [Related]
55. Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression.
Jia F; Yu Q; Wang R; Zhao L; Yuan F; Guo H; Shen Y; He F
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674985
[TBL] [Abstract][Full Text] [Related]
56. Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis.
Huang X; Hong X; Wang J; Sun T; Yu T; Yu Y; Fang J; Xiong H
EBioMedicine; 2020 Nov; 61():103037. PubMed ID: 33039709
[TBL] [Abstract][Full Text] [Related]
57. Prognostic and clinicopathological significance of Fusobacterium nucleatum in colorectal cancer: a systemic review and meta-analysis.
Kim Y; Cho NY; Kang GH
J Pathol Transl Med; 2022 May; 56(3):144-151. PubMed ID: 35581731
[TBL] [Abstract][Full Text] [Related]
58.
Chen Y; Chen Y; Zhang J; Cao P; Su W; Deng Y; Zhan N; Fu X; Huang Y; Dong W
Theranostics; 2020; 10(1):323-339. PubMed ID: 31903123
[No Abstract] [Full Text] [Related]
59. A Probiotic Formula for Modulation of Colorectal Cancer Risk via Reducing CRC-Associated Bacteria.
Liang JQ; Zeng Y; Lau EYT; Sun Y; Huang Y; Zhou T; Xu Z; Yu J; Ng SC; Chan FKL
Cells; 2023 Apr; 12(9):. PubMed ID: 37174650
[TBL] [Abstract][Full Text] [Related]
60. Association of Fusobacterium nucleatum infection and colorectal cancer: A Mexican study.
Cuellar-Gómez H; Ocharán-Hernández ME; Calzada-Mendoza CC; Comoto-Santacruz DA
Rev Gastroenterol Mex (Engl Ed); 2021 Jun; ():. PubMed ID: 34210555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
